Table 1.
Demographic and Clinical Characteristics From 20 Human Immunodeficiency Virus (HIV)–Infected Subjects With Acute Hepatitis C Virus (HCV) at Screening
| Subject (Study ID) | Age, y | Sex | HCV Genotype | Duration of HCV Infection, wk | HCV Clinical Symptomsa | Mode of HCV Acquisition | HCV RNA, log10 IU/mL | ALT, IU/L | CD4+ T-Cell Count, Cells/mm3 |
HAART During Study | HCV Virological Study Outcomec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screen | Nadirb | |||||||||||
| Co1 (101) | 35 | Male | 1a | 10 | Yes (3) | IDU | 4.98d | 52 | 437 | 238 | Yes | Unknown |
| Co2 (102) | 34 | Male | 1a | 16 | Yes (4) | IDU | 6.33 | 1066 | 630 | 448 | No | NR |
| Co3 (113) | 42 | Male | 1a | 6 | Yes (3, 4) | IDU | 5.28d | 630 | 650 | 189 | Yes | SVR |
| Co4 (116) | 36 | Male | 1a | 8 | No | Sexual | 6.75d | 762 | 342 | 291 | Yes | NR |
| Co5 (117) | 43 | Male | 4e | 20 | No | Other | 3.35 | 29 | 840 | 555 | No | Persist |
| Co6 (119) | 55 | Male | 3a | 8 | No | Sexual | 4.83 | 764 | 644 | 292 | Yes | SVR |
| Co7 (120) | 38 | Male | 1a | 9 | No | Sexual | 3.51 | 41 | 840 | 281 | Yes | SVR |
| Co8 (126) | 42 | Male | 1a | 6 | Yes (1, 2) | IDU | 6.57d | 2840d | 924 | 598 | Yes | SVR |
| Co9 (127) | 23 | Male | 1a | 25 | Yes (2) | Sexual | 6.42 | 333 | 828 | 880 | No | NR |
| Co10 (626) | 47 | Male | 3a | 7 | No | IDU | 5.91d | 334 | 400 | 361 | Yes | SVR |
| Co11 (628) | 49 | Male | 1a | 12 | No | Sexual | 3.83d | 315 | 642 | 56 | Yes | NR |
| Co12 (633) | 32 | Male | 1a | 17 | Yes (1) | IDU | 3.93 | 124 | 791 | 482 | No | SVR |
| Co13 (635) | 36 | Male | 3a | 25 | Yes (3–5) | Sexual | 1.00–2.97 | 217 | 506 | 8 | Yes | Clear |
| Co14 (636) | 39 | Male | 3a | 17 | Yes (1–3, 5) | Sexual | 5.75d | 2936d | 554 | 260 | Yes | SVR |
| Co15 (644) | 29 | Male | 1a | 16 | No | IDU | 1.00–2.97 | 145 | 391 | 312 | No | SVR |
| Co16 (648) | 46 | Male | 1b | 15 | Yes (1–3) | IDU | 6.03 | 181 | 565 | 54 | No | SVR |
| Co17 (810) | 44 | Male | 2a/c | 26 | No | Sexual | 6.51d | 112 | 340 | 203 | Yes | Reinfect |
| Co18 (2402) | 45 | Male | 1a | 15 | Yes (1–5) | Other | 3.44d | 82 | 1090 | 10 | Yes | Clear |
| Co19 (2403) | 52 | Male | 1b | 16 | Yes (3) | IDU | 5.61 | 420 | 510 | 476 | No | SVR |
| Co20 (2602) | 44 | Male | 1a | 8 | No | IDU | 5.25 | 560d | 510 | 342 | Yes | NR |
Abbreviations: ALT, alanine aminotransferase; HAART, highly active antiretroviral treatment; ID, identification number; IDU, injection drug use; NR, nonresponder; SVR, sustained virological responder.
a Specific clinical symptoms are indicated numerically: 1, jaundice; 2, nausea; 3, abdominal pain; 4, fever; 5, hepatomegaly.
b Nadir CD4+ T-cell counts were defined as the lowest CD4+ T-cell count after HIV infection, obtained historically from the patient's treating physician and/or clinical notes.
c Outcomes were defined as follows: clear, untreated subject with HCV clearance; NR, treated subject with viral persistence; persist, untreated subject with viral persistence; reinfect, subject who was reinfected; SVR, treated subject with HCV clearance who remained HCV negative; unknown, subject lost to follow-up before a study outcome was established.
d Peak RNA and ALT levels.